Study
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC (Hipo 015)
| Study ID | Alternative Stable ID | Type |
|---|---|---|
| EGAS00001007143 | Cancer Genomics |
Study Description
Study Datasets 2 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD00001010883 |
130 runs/ 65 samples of paired RNA-Seq data of chemo-naïve and post-chemotherapy pancreatic ductal adenocarcinoma (PDAC). The sequencing was done on Novaseq 6000 with Illumina TruSeq stranded mRNA Kit.
|
Illumina NovaSeq 6000 | 65 |
| EGAD00001010884 |
Paired RNA-Seq of 32 samples of chemo-naïve and post-chemotherapy PDAC tumors (HIPO_015) to define the molecular and cellular impact of neoadjuvant chemotherapy. Transcriptome analysis combined with high resolution mapping of whole tissue sections identified GATA6 (Classical), KRT17 (Basal-like) and Cytochrome P450 3A (CYP3A) co-expressing cells that were preferentially enriched in post-CTX resected samples. The sequencing was done on HiSeq2000/HiSeq2500 using the ... (Show More)
|
Illumina HiSeq 2000,Illumina HiSeq 2500 | 32 |
Who archives the data?
